DaVita Inc. $DVA Shares Bought by Atom Investors LP

Atom Investors LP boosted its stake in shares of DaVita Inc. (NYSE:DVA) by 56.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 71,796 shares of the company’s stock after purchasing an additional 25,799 shares during the period. DaVita makes up approximately 0.6% of Atom Investors LP’s portfolio, making the stock its 27th biggest holding. Atom Investors LP’s holdings in DaVita were worth $8,157,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Invesco Ltd. grew its position in DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after purchasing an additional 32,358 shares during the period. Morgan Stanley grew its position in DaVita by 5.1% during the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after purchasing an additional 71,156 shares during the period. Arrowstreet Capital Limited Partnership grew its position in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after purchasing an additional 636,191 shares during the period. Dimensional Fund Advisors LP grew its position in DaVita by 0.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock worth $123,733,000 after purchasing an additional 3,507 shares during the period. Finally, LSV Asset Management grew its position in DaVita by 1.1% during the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after purchasing an additional 9,739 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 0.4%

DVA stock opened at $208.91 on Wednesday. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $211.95. The stock has a market cap of $13.41 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 0.69 and a beta of 0.91. The business’s 50-day moving average is $178.66 and its 200 day moving average is $147.52.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same period in the previous year, the firm posted $2.00 EPS. DaVita’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on DVA. UBS Group increased their price target on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Truist Financial raised their target price on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and raised their target price for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $199.17.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.